Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fraudulent diabetes supplements

This article was originally published in The Tan Sheet

Executive Summary

FTC and FDA are collaborating with government agencies in Mexico and Canada to stop the fraudulent sale of supplements being marketed as diabetes treatments, according to an Oct. 19 announcement. Warning Letters sent by FDA to 24 dietary supplement manufacturers whose products claim to treat or prevent diseases coincide with an Internet sweep that resulted in FTC Warning Letters for deceptive advertising to 84 domestic and seven Canadian websites targeting U.S. consumers. FTC also has launched a consumer education initiative that teaches buyers to "Be smart, be skeptical!" and provides examples of fraudulent claims for a fictional product on a "teaser" website...

FTC and FDA are collaborating with government agencies in Mexico and Canada to stop the fraudulent sale of supplements being marketed as diabetes treatments, according to an Oct. 19 announcement. Warning Letters sent by FDA to 24 dietary supplement manufacturers whose products claim to treat or prevent diseases coincide with an Internet sweep that resulted in FTC Warning Letters for deceptive advertising to 84 domestic and seven Canadian websites targeting U.S. consumers. FTC also has launched a consumer education initiative that teaches buyers to "Be smart, be skeptical!" and provides examples of fraudulent claims for a fictional product on a "teaser" website....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel